On July 8, 2025, Silo Pharma, Inc. terminated a prior license agreement with the University of Maryland and entered into a new agreement giving them an exclusive option to negotiate a commercial license for certain peptides related to neuroinflammatory diseases. This agreement allows Silo to develop treatment options while having until March 31, 2026, to exercise the option by paying a $1,000 fee.